Penumbra, Inc. (PEN) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1159036,
    "name": "Penumbra, Inc.",
    "stock_name": "Penumbra, Inc.",
    "full_name": "Penumbra, Inc.",
    "name_url": "stocks-analysis/penumbra-inc",
    "exchange": 207,
    "exchangecode": "NYS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "294.72",
    "chg": 9.01,
    "chgp": "3.15%",
    "dir": 1,
    "prev_price": "285.71",
    "mcapval": "11,137.76",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2325,
    "indexname": "S&P 500",
    "isin": "US70975L1070",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "180.59 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/penumbra-inc-1159036-207&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Penumbra, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-penumbra-inc-overvalued-or-undervalued-3723363",
        "imagepath": "",
        "date": "2025-11-23 11:11:02",
        "description": "As of 21 November 2025, the valuation grade for Penumbra, Inc. moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company appears overvalued based on its high valuation ratios, including a P/E ratio of 84, an EV to EBITDA of 69.41, and a PEG ratio of 6.49, which are substantially higher than industry norms. In comparison, peers such as Hologic, Inc. have a P/E ratio of 21.83 and an EV to EBITDA of 14.71, showcasing a stark contrast in valuation metrics.\n\nDespite Penumbra's strong recent performance, with a year-to-date return of 21.47% compared to the S&P 500's 12.26%, the elevated valuation ratios suggest that the stock may not be justified at its current price level. The combination of these factors reinforces the conclusion that Penumbra, Inc. is overvalued in the current market...."
      },
      {
        "title": "Penumbra, Inc. Stock Hits 52-Week Low at USD 221.26",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/penumbra-inc-stock-hits-52-week-low-at-usd-22126-3671494",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/PenumbraInc_priceRelatedfactors_3671494.png",
        "date": "2025-11-04 17:52:08",
        "description": "Penumbra, Inc. has reached a new 52-week low of USD 221.26, reflecting recent market volatility. Despite this, the company has achieved a one-year performance of 20.28%, slightly surpassing the S&P 500. With a market cap of USD 11,138 million, Penumbra exhibits a P/E ratio of 84.00 and a return on equity of 11.41%."
      },
      {
        "title": "Penumbra, Inc. Experiences Revision in Its Stock Evaluation Amid Competitive Market Landscape",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/penumbra-inc-sees-valuation-grade-shift-from-very-expensive-to-expensive-3649064",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/PenumbraInc_valuationdot_3649064.png",
        "date": "2025-10-27 15:53:14",
        "description": "Penumbra, Inc., a small-cap company in the Pharmaceuticals & Biotechnology sector, has adjusted its valuation, with its current price at $252.99. Over the past year, it achieved a 22.48% stock return, surpassing the S&P 500. Key metrics indicate a premium valuation compared to industry peers."
      },
      {
        "title": "Is Penumbra, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-penumbra-inc-overvalued-or-undervalued-3637652",
        "imagepath": "",
        "date": "2025-10-21 12:06:30",
        "description": "As of 17 October 2025, the valuation grade for Penumbra, Inc. has moved from very expensive to expensive. The company appears to be overvalued based on its current metrics. Key ratios include a P/E ratio of 84, an EV to EBITDA of 69.41, and a PEG ratio of 6.49, all of which significantly exceed those of its peers. For instance, Hologic, Inc. has a P/E of 21.83 and an EV to EBITDA of 14.71, indicating that Penumbra is trading at a premium compared to its industry counterparts.\n\nIn terms of recent performance, Penumbra's stock has returned 23.11% over the past year, outperforming the S&P 500's 14.08% return, but it has lagged behind the index over longer periods, such as the 3-year and 5-year returns. This suggests that while the stock has shown some short-term strength, its high valuation ratios raise concerns about its sustainability moving forward...."
      },
      {
        "title": "Penumbra, Inc. Experiences Revision in Its Stock Evaluation Amid Competitive Market Landscape",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/penumbra-inc-sees-valuation-grade-downgrade-from-very-expensive-to-expensive-3640867",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/PenumbraInc_valuationdot_3640867.png",
        "date": "2025-10-20 16:44:31",
        "description": "Penumbra, Inc., a small-cap company in the Pharmaceuticals & Biotechnology sector, has a high valuation with a P/E ratio of 84 and a price-to-book value of 8.27. Its operational efficiency is reflected in a ROCE of 13.49% and ROE of 9.83%, while its stock performance has outpaced the S&P 500 over the past year."
      },
      {
        "title": "Is Penumbra, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-penumbra-inc-overvalued-or-undervalued-3634524",
        "imagepath": "",
        "date": "2025-10-20 12:23:57",
        "description": "As of 17 October 2025, Penumbra, Inc. has moved from a very expensive to an expensive valuation grade. The company is currently considered overvalued based on its high valuation ratios, including a P/E ratio of 84, an EV to EBITDA of 69.41, and a PEG ratio of 6.49. In comparison, peers such as Hologic, Inc. and The Cooper Companies, Inc. have P/E ratios of 21.83 and 34.28, respectively, indicating that Penumbra's valuation is significantly higher than its industry counterparts.\n\nDespite the lack of return data, it is important to note that Penumbra's stock price has fluctuated between a 52-week high of 310.00 and a low of 199.01, reflecting volatility that may not align with its current valuation metrics. Overall, the combination of high valuation ratios and the recent grade change suggests that Penumbra, Inc. is overvalued in the current market context...."
      },
      {
        "title": "Is Penumbra, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-penumbra-inc-overvalued-or-undervalued-3632060",
        "imagepath": "",
        "date": "2025-10-19 12:01:28",
        "description": "As of 17 October 2025, the valuation grade for Penumbra, Inc. has moved from very expensive to expensive, indicating a slight improvement in perceived value but still suggesting overvaluation. The company is considered overvalued based on its high valuation ratios, including a P/E ratio of 84, an EV to EBITDA of 69.41, and a PEG ratio of 6.49. In comparison, Hologic, Inc. has a more reasonable P/E of 21.83, while The Cooper Cos., Inc. shows an EV to EBITDA of 14.70, highlighting the significant disparity in valuation metrics.\n\nDespite a 1-year return of 23.11%, which outperformed the S&P 500's 14.08%, the longer-term performance reveals a concerning trend, with a 5-year return of only 16.36% compared to the S&P 500's 91.29%. This suggests that while Penumbra may have had some recent success, its high valuation ratios and underperformance relative to the broader market over longer periods indicate that it re..."
      },
      {
        "title": "Penumbra, Inc. Experiences Revision in Its Stock Evaluation Amid Competitive Market Landscape",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/penumbra-inc-sees-valuation-grade-shift-from-expensive-to-very-expensive-3617427",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/PenumbraInc_valuationdot_3617427.png",
        "date": "2025-10-13 15:45:52",
        "description": "Penumbra, Inc., a small-cap company in the Pharmaceuticals & Biotechnology sector, has experienced a valuation adjustment. Its financial metrics indicate a high P/E ratio and significant EV ratios. Despite a year-to-date return of 9.69%, it has outperformed the S&P 500 over the past year with a 35.26% return."
      },
      {
        "title": "Is Penumbra, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-penumbra-inc-overvalued-or-undervalued-3612683",
        "imagepath": "",
        "date": "2025-10-12 11:08:30",
        "description": "As of 10 October 2025, the valuation grade for Penumbra, Inc. has moved from expensive to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued, as evidenced by its high P/E ratio of 84, a Price to Book Value of 8.27, and an EV to EBITDA of 69.41, all of which are substantially above industry norms. \n\nIn comparison to peers, Penumbra's P/E ratio is notably higher than The Cooper Companies, which has a P/E of 34.28, and Baxter International, which stands at 28.68. The PEG ratio of 6.49 further underscores the overvaluation, as it suggests that the stock is priced excessively relative to its growth rate. While Penumbra has shown a strong return of 35.26% over the past year, this is still below the S&P 500's return of 13.36% during the same period, reflecting a disparity in performance relative to the broader market...."
      }
    ],
    "total": 19,
    "sid": "1159036",
    "stock_news_url": "https://www.marketsmojo.com/news/penumbra-inc-1159036"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Penumbra, Inc. overvalued or undervalued?

2025-11-23 11:11:02

As of 21 November 2025, the valuation grade for Penumbra, Inc. moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company appears overvalued based on its high valuation ratios, including a P/E ratio of 84, an EV to EBITDA of 69.41, and a PEG ratio of 6.49, which are substantially higher than industry norms. In comparison, peers such as Hologic, Inc. have a P/E ratio of 21.83 and an EV to EBITDA of 14.71, showcasing a stark contrast in valuation metrics. Despite Penumbra's strong recent performance, with a year-to-date return of 21.47% compared to the S&P 500's 12.26%, the elevated valuation ratios suggest that the stock may not be justified at its current price level. The combination of these factors reinforces the conclusion that Penumbra, Inc. is overvalued in the current market....

Penumbra, Inc. Stock Hits 52-Week Low at USD 221.26

2025-11-04 17:52:08

Penumbra, Inc. has reached a new 52-week low of USD 221.26, reflecting recent market volatility. Despite this, the company has achieved a one-year performance of 20.28%, slightly surpassing the S&P 500. With a market cap of USD 11,138 million, Penumbra exhibits a P/E ratio of 84.00 and a return on equity of 11.41%.

Penumbra, Inc. Experiences Revision in Its Stock Evaluation Amid Competitive Market Landscape

2025-10-27 15:53:14

Penumbra, Inc., a small-cap company in the Pharmaceuticals & Biotechnology sector, has adjusted its valuation, with its current price at $252.99. Over the past year, it achieved a 22.48% stock return, surpassing the S&P 500. Key metrics indicate a premium valuation compared to industry peers.

Is Penumbra, Inc. overvalued or undervalued?

2025-10-21 12:06:30

As of 17 October 2025, the valuation grade for Penumbra, Inc. has moved from very expensive to expensive. The company appears to be overvalued based on its current metrics. Key ratios include a P/E ratio of 84, an EV to EBITDA of 69.41, and a PEG ratio of 6.49, all of which significantly exceed those of its peers. For instance, Hologic, Inc. has a P/E of 21.83 and an EV to EBITDA of 14.71, indicating that Penumbra is trading at a premium compared to its industry counterparts. In terms of recent performance, Penumbra's stock has returned 23.11% over the past year, outperforming the S&P 500's 14.08% return, but it has lagged behind the index over longer periods, such as the 3-year and 5-year returns. This suggests that while the stock has shown some short-term strength, its high valuation ratios raise concerns about its sustainability moving forward....

Penumbra, Inc. Experiences Revision in Its Stock Evaluation Amid Competitive Market Landscape

2025-10-20 16:44:31

Penumbra, Inc., a small-cap company in the Pharmaceuticals & Biotechnology sector, has a high valuation with a P/E ratio of 84 and a price-to-book value of 8.27. Its operational efficiency is reflected in a ROCE of 13.49% and ROE of 9.83%, while its stock performance has outpaced the S&P 500 over the past year.

Is Penumbra, Inc. overvalued or undervalued?

2025-10-20 12:23:57

As of 17 October 2025, Penumbra, Inc. has moved from a very expensive to an expensive valuation grade. The company is currently considered overvalued based on its high valuation ratios, including a P/E ratio of 84, an EV to EBITDA of 69.41, and a PEG ratio of 6.49. In comparison, peers such as Hologic, Inc. and The Cooper Companies, Inc. have P/E ratios of 21.83 and 34.28, respectively, indicating that Penumbra's valuation is significantly higher than its industry counterparts. Despite the lack of return data, it is important to note that Penumbra's stock price has fluctuated between a 52-week high of 310.00 and a low of 199.01, reflecting volatility that may not align with its current valuation metrics. Overall, the combination of high valuation ratios and the recent grade change suggests that Penumbra, Inc. is overvalued in the current market context....

Is Penumbra, Inc. overvalued or undervalued?

2025-10-19 12:01:28

As of 17 October 2025, the valuation grade for Penumbra, Inc. has moved from very expensive to expensive, indicating a slight improvement in perceived value but still suggesting overvaluation. The company is considered overvalued based on its high valuation ratios, including a P/E ratio of 84, an EV to EBITDA of 69.41, and a PEG ratio of 6.49. In comparison, Hologic, Inc. has a more reasonable P/E of 21.83, while The Cooper Cos., Inc. shows an EV to EBITDA of 14.70, highlighting the significant disparity in valuation metrics. Despite a 1-year return of 23.11%, which outperformed the S&P 500's 14.08%, the longer-term performance reveals a concerning trend, with a 5-year return of only 16.36% compared to the S&P 500's 91.29%. This suggests that while Penumbra may have had some recent success, its high valuation ratios and underperformance relative to the broader market over longer periods indicate that it re...

Penumbra, Inc. Experiences Revision in Its Stock Evaluation Amid Competitive Market Landscape

2025-10-13 15:45:52

Penumbra, Inc., a small-cap company in the Pharmaceuticals & Biotechnology sector, has experienced a valuation adjustment. Its financial metrics indicate a high P/E ratio and significant EV ratios. Despite a year-to-date return of 9.69%, it has outperformed the S&P 500 over the past year with a 35.26% return.

Is Penumbra, Inc. overvalued or undervalued?

2025-10-12 11:08:30

As of 10 October 2025, the valuation grade for Penumbra, Inc. has moved from expensive to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued, as evidenced by its high P/E ratio of 84, a Price to Book Value of 8.27, and an EV to EBITDA of 69.41, all of which are substantially above industry norms. In comparison to peers, Penumbra's P/E ratio is notably higher than The Cooper Companies, which has a P/E of 34.28, and Baxter International, which stands at 28.68. The PEG ratio of 6.49 further underscores the overvaluation, as it suggests that the stock is priced excessively relative to its growth rate. While Penumbra has shown a strong return of 35.26% over the past year, this is still below the S&P 500's return of 13.36% during the same period, reflecting a disparity in performance relative to the broader market....

View All News